Universität zu Köln

Barbe, Anna Greta ORCID: 0000-0003-0169-2582, Schmidt-Park, Yasmin, Hamacher, Stefanie ORCID: 0000-0003-2158-9101, Derman, Sonja Henny Maria and Noack, Michael Johannes (2018). Efficacy of GUMA (R) Hydral versus BiotSneA (R) Oralbalance mouthwashes plus gels on symptoms of medication-induced xerostomia: a randomized, double-blind, crossover study. Clin. Oral Investig., 22 (1). S. 169 - 181. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1436-3771

Full text not available from this repository.

Abstract

The objective of this study is to determine the efficacy of GUMA (R) Hydral versus BiotSneA (R) Oralbalance (both a mouthwash plus gel) on the subjective burden and clinical symptoms of patients with medication-induced xerostomia. Subjects (N = 40) with medication-induced xerostomia (minimum 4/10 mm visual analog scale [VAS]) were randomized to treatment with GUM Hydral or BiotSne Oralbalance mouthwash, both with gel, for 28 days. Subjects then entered a 21-day wash-out period, before crossing over to the other treatment for 28 days. Outcomes measured included the VAS, German Oral Health Impact Profile (OHIPG)-14, Xerostomia Questionnaire (XQ), after-use questionnaire, and clinical parameters. Both GUM Hydral and BiotSne Oralbalance significantly (p < 0.05) reduced VAS, OHIPG-14 total score and single items, and XQ Part 1 (oral dryness, oral pain, taste loss) and Part 2 items. GUM Hydral also significantly reduced the XQ Part 1 dysphagia score, while BiotSne Oralbalance significantly reduced the halitosis organoleptic score and plaque index. Significant increases in saliva secretion did not reach clinical relevance. No significant between-group differences were observed, apart from OHIPG-14 items trouble pronouncing words and uncertainty in favor of GUM Hydral. No adverse effects were reported. Both products effectively improve oral health and xerostomia-related quality of life. However, they cannot completely substitute the continuous in-mouth secretion of saliva, and symptomatic relief is temporary. Product selection will be based on personal preference. Both products diminish xerostomic burden and should be part of the management strategy. Affected patients should be informed of these treatments, since no adverse effects were reported.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Barbe, Anna Greta UNSPECIFIED orcid.org/0000-0003-0169-2582 UNSPECIFIED Schmidt-Park, Yasmin UNSPECIFIED UNSPECIFIED UNSPECIFIED Hamacher, Stefanie UNSPECIFIED orcid.org/0000-0003-2158-9101 UNSPECIFIED Derman, Sonja Henny Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Noack, Michael Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-204844
DOI:	10.1007/s00784-017-2096-0
Journal or Publication Title:	Clin. Oral Investig.
Volume:	22
Number:	1
Page Range:	S. 169 - 181
Date:	2018
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1436-3771
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DRY MOUTH; WHOLE SALIVA; ORAL-HEALTH; RADIOTHERAPY; HEAD; LACTOPEROXIDASE; HYPOFUNCTION; SUBSTITUTES; TOOTHPASTE; BIOTENE Multiple languages Dentistry, Oral Surgery & Medicine Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/20484